Regeneron Stock: A Buy Despite Setbacks?

Regeneron (NASDAQ:REGN) appears as a compelling investment despite its shares trading down 11.45% year-to-date, even after a series of positive quarterly results. The company announced Q1 2026 revenue of $3.605 billion, exceeding estimates, with non-GAAP EPS of $9.47. Dupixent continues to be a major growth driver, achieving global sales of $4.88 billion in the quarter and serving over 1.4 million patients worldwide.

Further bolstering Regeneron's financial strength, the company holds $18.54 billion in cash and generated $848 million in free cash flow in Q1. A new $3.0 billion share repurchase program was authorized in April, alongside a $0.94 quarterly dividend. Analysts maintain a positive outlook, with a consensus target of $833.31 and 72% bullish sentiment.

Near-term catalysts include potential FDA approvals for fianlimab in metastatic melanoma and garetosmab, with a BLA decision expected in August 2026. Additionally, an NDA decision for cemdisiran is anticipated in Q4 2026. These pipeline developments, coupled with a strong balance sheet and share buybacks, present multiple avenues for growth, though concerns remain regarding legacy Eylea sales and upcoming biosimilar competition.